Drugs/Approval·openFDA

Dialyvite 3000 — Hillestad Pharmaceuticals USA drug label update

LowPublished Jan 27, 2027· AI-analyzed May 4, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

Hillestad Pharmaceuticals USA has updated the drug label for Dialyvite 3000, a prescription folic acid supplement intended for improving the nutritional status of patients undergoing renal dialysis.

Who it affects

This update affects Hillestad Pharmaceuticals USA, healthcare providers treating renal dialysis patients, and regulatory affairs professionals responsible for vitamin and supplement labeling within the prescription drug category.

Why it matters

The clarification of 'Indications and Usage' specifically for renal dialysis patients suggests a refined regulatory focus on ensuring the dosage and nutrient profile are correctly positioned for this vulnerable population. Regulatory teams should note the classification as a prescription supplement, which carries different compliance requirements compared to over-the-counter vitamins.

Practical takeaway

Regulatory and labeling teams should review the updated 'Indications and Usage' section to ensure internal product documentation and promotional materials align with the specific prescription status and renal dialysis focus. Verification of current inventory labels should be conducted to ensure compliance with the updated labeling.

FDA source material

Dialyvite 3000 (Hillestad Pharmaceuticals USA). INDICATIONS AND USAGE Dialyvite 3000 is a prescription folic acid supplement with additional nutrients indicated for use in improving the nutritional status of renal dialysis patients.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.